Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

13.6K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
13.6K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.5K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting the METTL1/m7G axis as a therapeutic strategy in myeloid leukemia.

Blood·2026
Same author

PTP4A2 promotes leukemogenesis through inhibiting the p53 tumor suppressor signaling pathway in leukemia-initiating cells.

Blood advances·2026
Same author

DDX6 undergoes phase separation to modulate metabolic plasticity and chemoresistance.

Nature communications·2025
Same author

ALKBH1 Drives Tumorigenesis and Drug Resistance via tRNA-decoding Reprogramming and Codon-biased Translation.

Cancer discovery·2025
Same author

Fusion-specific chromatin profiles mediate transcriptional heterogeneity in MLL-rearranged acute lymphoblastic leukemia.

Blood advances·2024
Same author

YTHDF2 promotes ATP synthesis and immune evasion in B cell malignancies.

Cell·2024
Same journal

Mammalian Respiratory Chain Complex Assemblies and Their Links to Mitochondria Stress-Induced Human Diseases.

Advances in experimental medicine and biology·2026
Same journal

Enzyme Assemblies in Nucleotide Metabolism: Structure, Regulation, and Disease Implications.

Advances in experimental medicine and biology·2026
Same journal

The Pyruvate Dehydrogenase Complex: A 90-Year-Old Enigma Shaping the Future of Structural Enzymology.

Advances in experimental medicine and biology·2026
Same journal

Regulation of the Anti-termination RNA Transcription Complex by Lon-Mediated Lambda N Degradation.

Advances in experimental medicine and biology·2026
Same journal

PCNA Macromolecular Complexes: PCNA Serves as a Molecular Hub Regulating Multiple Cellular Processes Inside and Outside of the Nucleus.

Advances in experimental medicine and biology·2026
Same journal

Dynamic Assemblies in Genome Maintenance.

Advances in experimental medicine and biology·2026
See all related articles

Related Experiment Video

Updated: Mar 6, 2026

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
09:16

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells

Published on: September 1, 2019

8.1K

RUNX1-ETO Leukemia.

Shan Lin1, James C Mulloy1, Susumu Goyama2

  • 1Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, Cincinnati, OH, USA.

Advances in Experimental Medicine and Biology
|March 17, 2017
PubMed
Summary
This summary is machine-generated.

AML1-ETO leukemia, a common acute myeloid leukemia subtype, involves the t(8;21) translocation. Research reveals its molecular pathogenesis, including DNA repair suppression and the critical balance with native AML1 for sustaining cancer cells.

Keywords:
AML1(RUNX1)AML1-ETO (RUNX1-ETO)Acute myeloid leukemiaDNA repairEpigeneticsSignal transductionTranscription factor complex

More Related Videos

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

10.5K
Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line
12:58

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line

Published on: May 10, 2017

9.9K

Related Experiment Videos

Last Updated: Mar 6, 2026

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells
09:16

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells

Published on: September 1, 2019

8.1K
Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells
10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

10.5K
Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line
12:58

Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line

Published on: May 10, 2017

9.9K

Area of Science:

  • Hematology
  • Molecular Biology
  • Genetics

Background:

  • AML1-ETO leukemia, characterized by the t(8;21) translocation, is a frequent cytogenetic subtype of acute myeloid leukemia (AML).
  • Significant advancements have been made in elucidating the molecular underpinnings of AML1-ETO leukemia.
  • The AML1-ETO oncoprotein interacts with transcription factors like E proteins, influencing gene expression.

Purpose of the Study:

  • To explore the molecular pathogenesis of AML1-ETO leukemia.
  • To investigate the role of AML1-ETO in DNA repair mechanisms.
  • To understand the significance of the balance between AML1-ETO and native AML1 in maintaining the leukemic phenotype.

Main Methods:

  • Proteomic surveys to identify protein complexes involving AML1-ETO.
  • Genome-wide transcriptome analysis to identify regulated genes.
  • Chromatin immunoprecipitation sequencing (ChIP-seq) to map AML1-ETO binding sites.

Main Results:

  • AML1-ETO forms stable complexes with transcription factors, including E proteins.
  • Genes such as CEBPA are directly regulated by AML1-ETO.
  • Evidence suggests AML1-ETO suppresses endogenous DNA repair, promoting mutagenesis and secondary genetic events.
  • A precise balance between AML1-ETO and native AML1 is crucial for the malignant cell phenotype.

Conclusions:

  • Understanding AML1-ETO's molecular interactions and regulatory functions provides insights into leukemia development.
  • The suppression of DNA repair by AML1-ETO is a key mechanism contributing to leukemogenesis.
  • Maintaining the delicate balance between AML1-ETO and native AML1 is essential for sustaining the leukemic state.
  • Clinical translation of these molecular findings is an emerging area of research.